Profile
| Metric | Value |
|---|---|
| Full Name | Dianthus Therapeutics, Inc. |
| Ticker | NASDAQ: DNTH |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | dianthustx.com |
| Employees | 78 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $44.48 | |
| Price, 1D Change | +13.70% | |
| Market Cap | $2B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.05 | |
| Revenue | $6M | |
| Revenue, 1Y Change | +120.63% | |
| EPS | -$2.55 | |
| EPS, 1Y Change | +69.82% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | N/A | |
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 1:16 | |
| Next Split | N/A | N/A |
| Last Ticker Change | MGTA | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$2.55 | |
| EPS Estimate | -$3.73 | |
| EPS Est. Change | -46.24% | |
| Revenue | $6.24M | |
| Revenue Estimate | $2.22M | |
| Revenue Est. Change | -64.39% | |
| Current Price | $44.48 | |
| Price Target | - | $64.00 |
| Price Tgt. Change | - | +43.88% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$5.21 | -$8.45 | -62.22% | |
| -$2.27 | -$2.55 | -12.36% | |
| -$3.73 | N/A | -46.24% | |
| -$3.87 | N/A | -51.66% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $2.32M | $2.83M | +21.81% | |
| $5.41M | $6.24M | +15.35% | |
| $2.22M | N/A | -64.39% | |
| $1.57M | N/A | -74.78% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +93.06% | |
| Price, 3Y | +8,137.04% | |
| Market Cap, 1Y | +166.03% | |
| Market Cap, 3Y | +93,085.01% | |
| Revenue, 1Y | +120.63% | |
| Revenue, 3Y | +100.00% | |
| EPS, 1Y | +69.82% | |
| EPS, 3Y | +87.69% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $44.48 | |
| SMA 200 | $28.02 | |
| SMA 200 vs Price | -37.00% | |
| SMA 50 | $40.28 | |
| SMA 50 vs Price | -9.44% | |
| Beta | 1.05 | |
| ATR | $2.05 | |
| 14-Day RSI | 45.15 | |
| 10-Day Volatility | 52.72% | |
| 1-Year Volatility | 68.54% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $6.24M | |
| EPS | -$2.55 | |
| Gross Profit | $5.82M | |
| Gross Margin | 93.39% | |
| Operating Profit | -$101.86M | |
| Operating Margin | -1,633.75% | |
| Net Income | -$84.97M | |
| Net Margin | -1,362.77% | |
| EBITDA | -$101.45M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.00 | |
| Current Ratio | 15.22 | |
| Quick Ratio | 15.22 | |
| - | ||
| F-Score | 1 | |
| Altman Z-Score | 51.90 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 619.60 | |
| PB Ratio | 3.49 | |
| EV/EBITDA | -10.76 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $352.48M | |
| Cash & Equivalents | $275.24M | |
| Total Assets | $374.24M | |
| Current Assets | $280.90M | |
| Total Liabilities | $21.76M | |
| Current Liabilities | $18.45M | |
| Total Debt | $1.49M | |
| Short Term Debt | $320.00K | |
| Accounts Payable | $4.58M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $91.20M | |
| Operating Expenses | $107.69M | |
| Cost Of Goods Sold | $412.00K | |
| SG&A | $0.00 | |
| D&A | $412.00K | |
| Interest Expense | $0.00 | |
| Income Tax | $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$78.18M | |
| CFI | -$286.81M | |
| CFF | $255.62M | |
| Capex | $105.00K | |
| Free Cash Flow | -$78.29M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Truist Securities | → | |
| Wedbush | → | |
| HC Wainwright & Co. | → | |
| Wedbush | → | |
| Truist Securities | ||
| Clear Street | ||
| Wedbush | → | |
| Stifel | → | |
| Raymond James | → | |
| Guggenheim | → |
Analyst sentiment
Institutional ownership
Screeners with DNTH
Data Sources & References
- DNTH Official Website dianthustx.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1690585/000119312525266920/0001193125-25-266920-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1690585/000095017025037131/0000950170-25-037131-index.htm
- DNTH Profile on Yahoo Finance finance.yahoo.com/quote/DNTH
- DNTH Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/dnth
FAQ
What is the ticker symbol for Dianthus Therapeutics, Inc.?
The ticker symbol for Dianthus Therapeutics, Inc. is NASDAQ:DNTH
Does Dianthus Therapeutics, Inc. pay dividends?
No, Dianthus Therapeutics, Inc. does not pay dividends
What sector is Dianthus Therapeutics, Inc. in?
Dianthus Therapeutics, Inc. is in the Healthcare sector
What industry is Dianthus Therapeutics, Inc. in?
Dianthus Therapeutics, Inc. is in the Biotechnology industry
What country is Dianthus Therapeutics, Inc. based in?
Dianthus Therapeutics, Inc. is headquartered in United States
When did Dianthus Therapeutics, Inc. go public?
Dianthus Therapeutics, Inc. initial public offering (IPO) was on June 21, 2018
Is Dianthus Therapeutics, Inc. in the S&P 500?
No, Dianthus Therapeutics, Inc. is not included in the S&P 500 index
Is Dianthus Therapeutics, Inc. in the NASDAQ 100?
No, Dianthus Therapeutics, Inc. is not included in the NASDAQ 100 index
Is Dianthus Therapeutics, Inc. in the Dow Jones?
No, Dianthus Therapeutics, Inc. is not included in the Dow Jones index
When was Dianthus Therapeutics, Inc. last earnings report?
Dianthus Therapeutics, Inc.'s most recent earnings report was on November 5, 2025
When does Dianthus Therapeutics, Inc. report earnings?
The next expected earnings date for Dianthus Therapeutics, Inc. is March 10, 2026